First Patient Treated In Cytori’s U.S. Cell Therapy Heart Failure Trial
October 11, 2012 - (Cytori) -"Cytori Therapeutics announced the initiation of the FDA approved ATHENA clinical trial to investigate Cytori’s cell therapy in patients who suffer from a severe form of refractory (untreatable) heart failure due to chronic myocardial ischemia. Cytori’s cell therapy is based on a patient’s own adipose-derived stem and regenerative cells (ADRCs) processed by the Company’s proprietary Celution® System technology, making this the first FDA approved trial in the U.S. to evaluate ADRCs for cardiovascular disease." Read Full Article
